Aligos Therapeutics (ALGS) EPS (Basic) (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly EPS (Basic) came in at -$0.14 in Q2 2026, up 90.59% on a YoY basis from -$0.08 in Q2 2025, and up 93.49% quarter-over-quarter from -$2.21 in Q1 2026.
Powered by 
Analysis
Aligos Therapeutics (ALGS) EPS (Basic) (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has reported EPS (Basic) for 8 consecutive years, with -$0.14 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EPS (Basic) rose 90.59% year-over-year to -$0.14; the trailing twelve-month figure through Jun 2026 stood at -$6.77 (up 5.51% YoY), and the FY2025 full-year result was -$1.91, up 90.89% from the prior year.
- EPS (Basic) advanced to -$0.14 in Q2 2026 per ALGS's latest filing, from -$2.21 in the prior quarter.
- Across five years, EPS (Basic) topped out at $5.12 in Q1 2025 and bottomed at -$13.11 in Q4 2024.
- Historically, EPS (Basic) has averaged -$1.32 across 5 years, with a median of -$0.49 in 2022.
- The widest YoY moves for EPS (Basic): up 2395.24% in 2025, down 4837.2% in 2025.
- Over 5 years, EPS (Basic) stood at -$0.51 in 2022, then rose by 15.33% to -$0.43 in 2023, then plunged by 2921.19% to -$13.11 in 2024, then soared by 88.77% to -$1.47 in 2025, then soared by 90.21% to -$0.14 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.14, -$2.21, and -$1.47 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -0.40 |
| 10 | Aligos Therapeutics | 54.92 Mn | 24.48 Mn | - | -0.14 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.14 |
| Mar 31, 2026 | -2.21 |
| Dec 31, 2025 | -1.47 |
| Sep 30, 2025 | -3.04 |
| Jun 30, 2025 | -1.53 |
| Mar 31, 2025 | 5.12 |
| Dec 31, 2024 | -13.11 |
| Sep 30, 2024 | -3.07 |
| Jun 30, 2024 | 0.03 |
| Mar 31, 2024 | -0.22 |
| Dec 31, 2023 | -0.43 |
| Sep 30, 2023 | -0.41 |
| Jun 30, 2023 | -0.43 |
| Mar 31, 2023 | -0.53 |
| Dec 31, 2022 | -0.51 |
| Sep 30, 2022 | -0.44 |
| Jun 30, 2022 | -0.47 |
| Mar 31, 2022 | -0.84 |
| Dec 31, 2021 | -0.95 |
| Sep 30, 2021 | -0.78 |